Tanomastat

Tanomastat is an inhibitor of matrix metalloproteinase-2 (MMP-2), MMP-3, and MMP-9 (Kis = 11, 143, and 301 nM, respectively). It is selective for MMP-2, -3, and -9 over MMP-1 and MMP-13 (Kis = 5,000 and 1,470 nM, respectively). Tanomastat (15 µM) inhibits VEGF- and FGF-induced tubule formation in human umbilical vein endothelial cells (HUVECs). It reduces tumor growth and the number of pulmonary metastases in an MDA-MB-435 orthotopic mouse model of breast cancer when administered at a dose of 100 mg/kg. Tanomastat (50 mg/kg) decreases disease severity in a rat model of adjuvant-induced arthritis.Formal Name: 4'-chloro-gamma-oxo-alphaS-[(phenylthio)methyl]-[1,1'-biphenyl]-4-butanoic acid. CAS Number: 179545-77-8. Synonyms: BAY 12-9566. Molecular Formula: C23H19ClO3S. Formula Weight: 410.9. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 25 mg/ml, DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml, DMSO: 25 mg/ml, Ethanol: 12 mg/ml. lambdamax: 285 nm. SMILES: ClC1=CC=C(C2=CC=C(C(C[C@@H](C(O)=O)CSC3=CC=CC=C3)=O)C=C2)C=C1. InChi Code: InChI=1S/C23H19ClO3S/c24-20-12-10-17(11-13-20)16-6-8-18(9-7-16)22(25)14-19(23(26)27)15-28-21-4-2-1-3-5-21/h1-13,19H,14-15H2,(H,26,27)/t19-/m1/s1. InChi Key: JXAGDPXECXQWBC-LJQANCHMSA-N.